 Participants eligible for the window therapy will receive two courses 21 days duration each of mTOR inhibitor, temsirolimus, in combination with temozolomide and irinotecan. Irinotecan 20 mgm2 will be administered IV on a protracted schedule of daily for 5 days, 2 days off, repeated daily x 5 qdx5x2, temozolomide 100 mgm2 PO daily x 5 days and temsirolimus 35 mgm2 IV weekly on day 1 and 8. Following window treatment weeks 1 - 6, participants will proceed to induction chemotherapy weeks 7 - 33 consisting of interval compressed every 2 weeks alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide VDC with ifosfamide and etoposide IE. Doxorubicin will be omitted following a total cumulative dose of 375 mgm2. Local control measures surgery andor radiation therapy will be instituted after 6 courses of induction chemotherapy week 19. Participants whose tumors respond to window therapy will receive temsirolimus, temozolomide and irinotecan at weeks 29 and 31 in place of ifosfamide and etoposide. Following induction therapy, participants will receive six 21-day courses of maintenance therapy consisting of bevacizumab IV on day 1 and daily oral sorafenib and low-dose cyclophosphamide day 1 through day 21. 